In last trading session, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) saw 7.65 million shares changing hands with its beta currently measuring 0.94. Company’s recent per share price level of $0.67 trading at $0.03 or 5.38% at ring of the bell on the day assigns it a market valuation of $242.85M. That closing price of LXRX’s stock is at a discount of -265.67% from its 52-week high price of $2.45 and is indicating a premium of 58.21% from its 52-week low price of $0.28. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 7.87 million shares which gives us an average trading volume of 15.29 million if we extend that period to 3-months.

For Lexicon Pharmaceuticals Inc (LXRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.1 in the current quarter.

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information

Upright in the green during last session for gaining 5.38%, in the last five days LXRX remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $0.67 price level, adding 2.9% to its value on the day. Lexicon Pharmaceuticals Inc’s shares saw a change of -9.03% in year-to-date performance and have moved 31.19% in past 5-day. Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) showed a performance of 83.85% in past 30-days. Number of shares sold short was 43.88 million shares which calculate 1.41 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 88.83% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -795.52% in reaching the projected high whereas dropping to the targeted low would mean a loss of -795.52% for stock’s current value.

Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts

This year revenue growth is estimated to fall -69.95% from the last financial year’s standing.

3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.18M for the same. And 3 analysts are in estimates of company making revenue of 1.31M in the next quarter. Company posted 1.13M and 1.65M of sales in current and next quarters respectively a year earlier.

In 2025, company’s earnings growth rate is likely to be around 42.06% while estimates for its earnings growth in next 5 years are of 38.72%.

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders

Insiders are in possession of 1.17% of company’s total shares while institution are holding 84.14 percent of that, with stock having share float percentage of 85.13%. Investors also watch the number of corporate investors in a company very closely, which is 84.14% institutions for Lexicon Pharmaceuticals Inc that are currently holding shares of the company. ARTAL GROUP S.A. is the top institutional holder at LXRX for having 175.1 million shares of worth $294.17 million. And as of 2024-06-30, it was holding 56.3318 of the company’s outstanding shares.

The second largest institutional holder is FMR LLC, which was holding about 38.69 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.4462 of outstanding shares, having a total worth of $64.99 million.

On the other hand, Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund are the top two Mutual Funds which own company’s shares. As of Feb 28, 2025 , the former fund manager was holding 16.86 shares of worth $11.33 million or 4.66% of the total outstanding shares. The later fund manager was in possession of 5.4 shares on Feb 28, 2025 , making its stake of worth around $3.63 million in the company or a holder of 1.49% of company’s stock.